Skip to content
DataLookout
Menu

NCT07342478

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 6 → 9 locations
  2. Minor Study sites: 8 to 9
  3. Minor Study sites: 7 to 8
  4. Notable Eligibility criteria expanded, about 17 words
    • Study sites: 6 to 7
    • Secondary endpoints: details revised at 3 of 7 entries
  5. Minor Study sites: 5 to 6v6
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 4 to 5v5
  2. Minor Study sites: 3 to 4v4
  1. Notable Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Jan 30, 2026 to Apr 23, 2026
    v3
  2. Notable Eligibility criteria shortened, about 29 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Study title expanded, about 3 words
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

PFS assessed by IRC
Timeframe: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Secondary (7)

OS
PFS assessed by INV
ORR
DOR
TTNT
Show 2 moreShow less
EFS
Safety and tolerability

Arms and interventions

RocbrutinibExperimental

200mg daily

PirtobrutinibActive comparator

200mg daily

Drugs: Rocbrutinib, Pirtobrutinib

Sites

10 sites in 2 countries

United States 7, France 3